BAM
RGNX icon

Belpointe Asset Management’s Regenxbio RGNX Stock Holding History

Belpointe Asset Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$3.78K – 2740
2023
Q1 		$3.78K Hold
200
– – ﹤0.01% 3112
2022
Q4 		$4.54K Buy
+200
New +$4.52K ﹤0.01% 2971

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Belpointe Asset Management's RGNX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Regenxbio (RGNX) in Q2 2023, closing a stake of 200 shares — an estimated $3.78K sold.

Belpointe Asset Management first reported a position in RGNX in Q4 2022 and held it in 2 quarters. The position peaked at $4.54K in Q4 2022. 167 funds tracked by Wall St. Rank hold RGNX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Regenxbio position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 200 Regenxbio shares in Q2 2023, an estimated $3.78K.
  • Belpointe Asset Management first reported a position in Regenxbio in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Regenxbio position peaked at $4.54K in Q4 2022.
  • 167 funds tracked by Wall St. Rank held Regenxbio as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.